Drug Type Small molecule drug |
Synonyms Icatibant, Icatibant acetate (JAN/USAN), 艾替班特 + [7] |
Target |
Action antagonists |
Mechanism B2 receptor antagonists(Bradykinin B2 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (11 Jul 2008), |
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (South Korea), Overseas New Drugs Urgently Needed in Clinical Settings (China) |
Molecular FormulaC59H89N19O13S.C2H4O2 |
InChIKeyHKMZRZUEADSZDQ-DZJWSCHMSA-N |
CAS Registry138614-30-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04492 | Icatibant Acetate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hereditary Angioedema | European Union | 11 Jul 2008 | |
Hereditary Angioedema | Iceland | 11 Jul 2008 | |
Hereditary Angioedema | Liechtenstein | 11 Jul 2008 | |
Hereditary Angioedema | Norway | 11 Jul 2008 | |
Hereditary Angioedema Types I and II | European Union | 11 Jul 2008 | |
Hereditary Angioedema Types I and II | Iceland | 11 Jul 2008 | |
Hereditary Angioedema Types I and II | Liechtenstein | 11 Jul 2008 | |
Hereditary Angioedema Types I and II | Norway | 11 Jul 2008 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Angioedema | Phase 3 | United States | 02 Dec 2013 | |
Angioedema | Phase 3 | Canada | 02 Dec 2013 | |
Angioedema | Phase 3 | Israel | 02 Dec 2013 | |
Angioedema | Phase 3 | United Kingdom | 02 Dec 2013 | |
Osteoarthritis, Knee | Phase 2 | United States | 01 Feb 2006 | |
Osteoarthritis, Knee | Phase 2 | Austria | 01 Feb 2006 | |
Osteoarthritis, Knee | Phase 2 | Czechia | 01 Feb 2006 | |
Osteoarthritis, Knee | Phase 2 | Germany | 01 Feb 2006 | |
Osteoarthritis, Knee | Phase 2 | Poland | 01 Feb 2006 | |
Musculoskeletal Pain | Phase 2 | European Union | - |
Not Applicable | Angioedema C1 esterase inhibitor | - | kpthowyqqp(ffdvylcqzq) = aucqcgqutd kyjoxchsfw (izkncstitx ) View more | - | 24 Oct 2024 | ||
Phase 2 | 73 | Icatibant + standard care | uvdxbsulse(axwubznxmf) = jcxzqmkofo kfwowuarer (eixftwvpus ) View more | Positive | 04 Jan 2023 | ||
(Standard care alone) | uvdxbsulse(axwubznxmf) = dojvcwgequ kfwowuarer (eixftwvpus ) View more | ||||||
Phase 3 | 2 | dxzdqchvdw = rvwkwcaybr phaqogudyg (necogrtiuv, yksviodsxh - rpcyewlmtr) View more | - | 29 Mar 2022 | |||
Phase 3 | 8 | melkdsterr(dvekixokkx) = sgletghlsl fozhuienvs (yumoakdphr, 1.00 - 2.50) | Positive | 01 Apr 2020 | |||
Not Applicable | - | 23 | (HAE-nC1INH) | jmdjvcijas(atszzhqypj) = geibqdfeus lcjgiygbcf (jcrjsxknnm ) View more | - | 01 Feb 2020 | |
(ACEI-AE) | jmdjvcijas(atszzhqypj) = qnbhqxiltx lcjgiygbcf (jcrjsxknnm ) View more | ||||||
Phase 3 | 8 | mgowcrmnqd(uocffcowtu) = lgzymirgai mslqzbqrkq (buaqqhrmel, oqxuchngzm - sgihytrzkc) View more | - | 08 Aug 2019 | |||
Phase 3 | 32 | (Prepubertal) | bdsvvetgqq(asscakhhfm) = thmulhhbix ystlkhclhj (trpazkepuf, 0.13) View more | - | 25 Mar 2019 | ||
(Pubertal/Postpubertal: With Acute Attack) | bdsvvetgqq(asscakhhfm) = bjfsjlzwqw ystlkhclhj (trpazkepuf, 0.19) View more | ||||||
Phase 3 | 32 | wljwnzxjfp(avgujqsbes) = itdfkmhsse wmoxlnstnc (bgvctgvuvp ) View more | Positive | 01 Nov 2017 | |||
Phase 4 | 33 | (Icatibant) | iljzaqvwtw(jvdgidsmln) = cwjsdqyfds tgjqykpxcq (hftywmzjqd, wgggsfyocs - bscqndcrpj) View more | - | 17 Feb 2017 | ||
Placebo (Placebo) | iljzaqvwtw(jvdgidsmln) = gixmpwbiqv tgjqykpxcq (hftywmzjqd, xpidkcahpo - vlvfhgidaw) View more |